MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $104.29M
• Dividend Yield: N/A
• Average Volume (3M): 814.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: 303.47%
• EPS Growth: 73.70%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 63,205,704
• 10 Day Avg. Volume: 1,152,816
• 30 Day Avg. Volume: 814,758
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.07
• Enterprise Value/Revenue: 0.05
• Enterprise Value/Gross Profit: 0.05
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: $4.50
• Price Target Upside: 172.73% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-9.09% Downside)

MacroGenics' overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and cash flow management issues. Technical analysis provides a slightly positive outlook with some bullish momentum, but valuation remains weak due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Positive revenue growth indicates expanding market reach and product adoption, which is crucial for long-term sustainability in the competitive biotech industry.

Gross Profit Margin

A high gross profit margin reflects efficient production processes and strong pricing power, which can support profitability as the company scales.

Cash Infusion

The cash infusion from the royalty agreement enhances financial flexibility, extending the cash runway through 2027, supporting ongoing operations and strategic initiatives.

Negative Factors

Profitability Issues

Ongoing profitability challenges, as indicated by a negative net profit margin, could hinder the company's ability to reinvest in R&D and growth initiatives.

Negative Return on Equity

A negative return on equity suggests inefficiencies in generating returns from shareholder investments, which may affect investor confidence and capital raising ability.

Leadership Change

Leadership changes can lead to strategic shifts and potential disruptions. The new CEO's focus on capital efficiency may alter the company's strategic direction and operational priorities.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

How the Company Makes Money

MacroGenics generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money from product sales once its drugs receive regulatory approval and are launched into the market. In addition to direct sales, MacroGenics also benefits from collaborative agreements and partnerships with larger pharmaceutical companies, which can include upfront payments, milestone payments based on the achievement of development goals, and royalties on future product sales. These partnerships allow MacroGenics to leverage the resources and expertise of larger entities while sharing the financial risks associated with drug development. Furthermore, the company may also receive funding through grants or government programs aimed at supporting innovative healthcare solutions.

MacroGenics Financial Statement Overview

Summary

MacroGenics faces significant financial challenges, with profitability and liquidity being major concerns. Despite strong gross profit margins, the company struggles with negative EBIT and net profit margins, indicating ongoing operational challenges.

Income Statement

MacroGenics has shown inconsistent revenue growth, with a significant increase in 2023 but a decline in 2024. The gross profit margin remains strong, but the company struggles with negative EBIT and net profit margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reflects moderate stability with a manageable debt-to-equity ratio. However, the declining stockholders' equity and high liabilities suggest potential financial strain. The equity ratio is decreasing, indicating a reliance on debt financing.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicating liquidity challenges. The free cash flow to net income ratio is negative, highlighting the company's difficulty in converting earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	152.43M	148.34M	57.19M	151.94M	75.64M	97.76M
Gross Profit	136.84M	136.04M	48.97M	144.56M	72.99M	-95.44M
EBITDA	-47.33M	-57.37M	2.02M	-107.89M	-190.86M	-117.78M
Net Income	-55.81M	-66.97M	-9.06M	-120.02M	-190.86M	-117.78M
Balance Sheet
Total Assets	224.56M	261.65M	298.42M	280.47M	335.25M	378.74M
Cash, Cash Equivalents and Short-Term Investments	154.14M	201.67M	229.81M	154.35M	243.62M	272.53M
Total Debt	37.47M	37.46M	33.97M	34.83M	25.47M	29.25M
Total Liabilities	145.45M	145.60M	145.81M	138.46M	95.63M	82.86M
Stockholders Equity	79.12M	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow
Free Cash Flow	-72.40M	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
Operating Cash Flow	-69.62M	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
Investing Cash Flow	134.41M	149.30M	-80.08M	70.72M	-36.61M	-7.79M
Financing Cash Flow	430.00K	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Negative. The current price of 1.65 is below the 20-day moving average (MA) of 1.70, above the 50-day MA of 1.62, and below the 200-day MA of 2.10, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 7.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	52 Neutral	$165.76M	―	-68.93%	―	-72.45%	-28.60%
Sector *	51 Neutral	$8.02B	-0.39	-43.38%	2.20%	22.34%	-2.13%
VXRT	47 Neutral	$86.99M	―	-100.35%	―	479.58%	46.15%
MGNX	46 Neutral	$104.29M	―	-69.71%	―	303.47%	73.70%
PLRX	37 Underperform	$101.29M	―	-67.55%	―	―	-9.87%
TNYA	36 Underperform	$211.87M	―	-85.21%	―	―	38.94%
ELTX	30 Underperform	$189.20M	―	-9999.00%	―	―	-4.60%

MacroGenics Corporate Events

MacroGenics Appoints Eric Risser as New CEO

On August 13, 2025, MacroGenics announced the appointment of Eric Risser as President, Chief Executive Officer, and Director, succeeding Scott Koenig, who led the company for 24 years. Risser, previously the Chief Operating Officer, aims to focus on creating a capital-efficient biotechnology company that delivers novel therapies for cancer patients, reflecting a strategic shift in leadership and vision for the company’s future.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.